Compare General Motors Company (GM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs BIO-TECHNE Corp — how do they compare? General Motors Company trades at $82.5 (market cap $71.06B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: General Motors Company is far larger — about 6.2× BIO-TECHNE Corp's market cap, and General Motors Company pays the higher dividend (0.89%). Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and BIO-TECHNE Corp for 63 Days on average.
| GM | TECH | |
|---|---|---|
Market Cap | $71.06B | $11.37B |
Volume | 6,269,264 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $72.61 |
52-Week Low | $55.35 | $43.31 |
Typical Hold Time | 83 Days | 63 Days |
Enterprise Value | $174.04B | $11.40B |
Dividend Yield | 0.89% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.25, up 0.29% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with declining revenue and net income margins (1.05% in 2025) but attractive valuation ratios including P/S of 0.41. Recent news highlights competitive pressures as Toyota narrows the U.S. sales gap and Q3 2026 sales fell 5.5% amid EV challenges.
GM faces headwinds from market share erosion and profitability pressure, though analyst consensus remains bullish with a $102.08 price target. Investment appeal hinges on execution amid industry transition, with risks including high debt levels and competitive threats from Asian automakers.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
